查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1919299

甲基丙二酸血症治疗市场：依治疗方法、给药途径、病患年龄层和通路－2026-2032年全球预测

Methylmalonic Acidemia Treatment Market by Treatment Type, Route Of Administration, Patient Age Group, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年甲基丙二酸血症治疗市场价值为 1.8497 亿美元，预计到 2026 年将成长至 2.0158 亿美元，预计到 2032 年将达到 2.5463 亿美元，复合年增长率为 4.67%。

关键市场统计数据
基准年 2025 1.8497亿美元
预计年份：2026年 2.0158亿美元
预测年份 2032 2.5463亿美元
复合年增长率 (%) 4.67%

本文简要概述了甲基丙二酸血症复杂的治疗现状、临床挑战以及影响治疗路径的相关人员趋势。

甲基丙二酸血症 (MMA) 的临床环境复杂多变，对临床医生、看护者和行业相关人员相关者都提出了挑战。本执行摘要回顾了目前的治疗现状，重点阐述了新的科学进展、不断发展的护理标准以及治疗实施过程中面临的实际挑战之间的相互作用。其目的是提供一个简洁而全面的概述，为研发优先事项、临床策略和商业化计画的製定提供依据。

医疗保健领域的新科学进步和创新正在重塑关于甲基丙二酸血症治疗方案、诊断和报销的讨论。

由于科学创新、监管法规的不断改进以及治疗模式的日趋成熟，甲基丙二酸血症（MMA）的治疗格局正在改变。基因治疗候选药物和先进的酵素替代疗法正从早期研究阶段迈向更为明确的临床项目，这促使人们重新评估长期治疗策略。同时，新生儿筛检灵敏度的提高和基因检测范围的扩大，使得早期诊断成为可能，从而改变了临床医生考虑的干预时机和干预类型。

2025年的关税趋势正促使人们重新评估全球供应链、筹资策略和本地製造决策，这些都会影响关税待遇的可及性和营运韧性。

2025年美国关税环境将影响MMA治疗生态系统的多个方面，包括供应链、定价策略和跨境采购决策。高度依赖进口的组件（例如，特殊试剂、生物中间体和基因治疗载体）如果因关税调整而导致成本上涨，可能会面临采购挑战，因此需要製定积极主动的筹资策略和库存计划。这些变化迫使製造商和经销商重新评估其采购合约和紧急方案，以维持供应的连续性并应对成本压力。

将治疗方法、给药途径、分销管道和年龄组与策略性临床和商业性要务联繫起来的基于细分市场的综合分析

详细的市场細項分析揭示了治疗方法方案、分销模式、给药途径和患者人口统计特征如何相互作用，从而影响临床选择和商业性路径。根据治疗类型，市场可分为饮食疗法、酵素替代疗法、基因疗法、造血干细胞移植和肝臟移植。饮食疗法又可细分为左旋肉碱补充剂、低蛋白饮食和维生素B12补充剂。这些治疗方法涵盖了从支持性治疗到潜在根治性介入的连续过程，凸显了将实证医学证据的产生与长期疗效指标结合的必要性。根据分销管道，市场分析涵盖医院和零售药局，重点关注医疗机构和配药基础设施对药物可近性、依从性和病患支援服务的影响。根据给药途径，市场分析涵盖静脉注射注射和口服给药方案，重点在于给药物流、医疗环境和病患生活方式因素如何影响治疗方法的采纳。根据患者年龄组，市场分析涵盖成人、婴儿和儿童群体，重点在于生命週期中临床表现、给药策略和监测要求的差异。

诊断、监管路径和医疗保健基础设施的区域差异，导緻美洲、欧洲、中东和非洲以及亚太地区的战略重点有所不同。

区域趋势在塑造甲基丙二酸血症（MMA）的临床、监管和商业性格局方面发挥关键作用，每个地区都呈现出独特的机会和挑战。在美洲，医疗保健系统在报销政策和新生儿筛检计画方面存在差异，这会影响诊断时机和新治疗方法的应用。该地区也集中了大量的专科治疗中心和临床研究活动，这有利于快速迭代试验设计和收集真实世界证据。该地区的患者权益倡导网络积极参与政策制定和支付方讨论，从而影响着患者的治疗途径。

产业参与者正透过产品线创新、製造伙伴关係以及将临床价值与真实世界证据相结合的综合患者支持模式来实现差异化竞争。

主要企业的活动和策略姿态正在塑造竞争格​​局，相关人员透过其临床研发管线、伙伴关係和实证方法实现差异化竞争。一些机构专注于投资载体优化、生产规模化和长期安全监测通讯协定，以推动基因治疗平台实现缓解疾病。另一些机构则优先考虑疗效的逐步提升和耐受性的改善，重点关注可整合到现有临床工作流程中的酵素替代疗法和支持性治疗方案。

透过伙伴关係、增强生产韧性以及与支付方合作，采取切实可行的、基于证据的步骤，将科学进步转化为可及且永续的医疗保健服务。

透过在研发、监管沟通和商业化准备的各个阶段优先采取协作策略，产业领导者可以采取果断措施，将科学潜力与持久的患者获益联繫起来。首先，将对患者、看护者和支付方至关重要的结果纳入临床开发计划，可以加强医保报销方面的讨论，并支持长期应用。这意味着，除了传统的生化指标外，还应设计能够捕捉功能性结果、生活品质指标和健康经济学终点的试验和註册研究。

一个透明的、多方法的研究框架，结合证据综合、专家参与和同侪检验，为MMA护理中的策略决策提供支援。

本研究采用多种方法，以确保研究结果的可靠性和可重复性，从而为临床和商业性相关人员相关者提供参考。调查方法结合了系统性文献综述、监管文件分析、同行评审临床证据的综合分析以及结构化访谈和专家咨询会议等定性研究手段。研究人员对临床试验註册库、指南库和公共文件的数据进行三角验证，以全面了解治疗方案的开发和诊疗路径。

整合临床进展、营运准备和相关人员合作，确保甲基丙二酸血症领域的创新能转化为持久的病患获益。

总之，甲基丙二酸血症的治疗模式正处于关键转折点。科学进步、政策演变和实际操作相互交织，为相关人员创造了新的机会和责任。新兴治疗方法有望改变疾病的长期进程，但要实现这一目标，需要严谨的证据收集、稳健的供应链以及支付方和医疗服务提供者的通力合作。透过扩大新生儿筛检和采用整合式医疗模式进行早期诊断，对于及时介入和改善治疗效果至关重要。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 甲基丙二酸血症治疗市场（依治疗方法划分）

  • 饮食疗法
    • 左旋肉碱补充剂
    • 低蛋白饮食
    • 维生素B12替代疗法
  • 酵素替代疗法
  • 基因治疗
  • 造血干细胞移植
  • 肝臟移植

9. 甲基丙二酸血症治疗市场（依给药途径划分）

  • 静脉注射
  • 口服

第十章 依患者年龄层分類的甲基丙二酸血症治疗市场

  • 成人版
  • 婴儿
  • 儿童

第十一章 甲基丙二酸血症治疗市场（依分销管道划分）

  • 医院药房
  • 零售药房

12. 各地区甲基丙二酸血症治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 甲基丙二酸血症治疗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国甲基丙二酸血症治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章美国甲基丙二酸血症治疗市场

第十六章 中国甲基丙二酸血症治疗市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Acer Therapeutics Inc.
  • Amgen Inc.
  • Aurobindo Pharma Limited
  • Baxter International Inc.
  • BioMarin Pharmaceutical Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius Kabi AG
  • Homology Medicines, Inc.
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Nestle Health Science SA
  • Nutricia BV
  • OrphanPacific, Inc.
  • Reckitt Benckiser Group plc
  • REGENXBIO Inc.
  • Rocket Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Ultragenyx Pharmaceutical Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-F14BA1B3419C

The Methylmalonic Acidemia Treatment Market was valued at USD 184.97 million in 2025 and is projected to grow to USD 201.58 million in 2026, with a CAGR of 4.67%, reaching USD 254.63 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 184.97 million
Estimated Year [2026] USD 201.58 million
Forecast Year [2032] USD 254.63 million
CAGR (%) 4.67%

A concise orientation to the complex therapeutic landscape, clinical imperatives, and stakeholder dynamics shaping care pathways for methylmalonic acidemia

Methylmalonic acidemia (MMA) presents a complex and evolving clinical landscape that challenges clinicians, caregivers, and industry stakeholders alike. This executive summary frames the current therapeutic environment, emphasizing the interplay between emerging scientific advances, evolving standards of care, and the logistical realities of treatment delivery. The intent is to offer a concise yet comprehensive orientation that primes leaders for informed decision-making across R&D prioritization, clinical strategy, and commercialization planning.

The introduction synthesizes recent developments in diagnostic precision, newborn screening expansion, and shifts in treatment paradigms that are reshaping patient pathways. It also highlights how multidisciplinary care teams and patient advocacy groups are influencing treatment adoption and care standards. By setting a clear context, this section makes explicit the critical linkages between clinical needs, technology maturation, and market dynamics that stakeholders must navigate to optimize outcomes for patients with MMA.

Emerging scientific advances and care delivery innovations are reshaping therapeutic choices, diagnostics, and reimbursement conversations across methylmalonic acidemia care

The MMA landscape is undergoing transformative shifts driven by scientific innovation, regulatory evolution, and the maturation of care delivery models. Gene therapy candidates and advanced enzyme replacement approaches are moving from early-phase studies into more defined clinical programs, prompting reassessment of long-term management strategies. Concurrently, improvements in newborn screening sensitivity and broader genetic panels are increasing early diagnosis, which alters the timing and type of interventions clinicians consider.

In parallel, payer frameworks and reimbursement dialogues are adapting to high-cost, high-value therapies, prompting stakeholders to develop robust evidence generation plans that demonstrate meaningful clinical benefits and durable outcomes. Treatment delivery is also evolving; for example, the roles of hospital-administered therapies versus outpatient or home-based management are being re-evaluated in light of safety, cost, and patient quality-of-life considerations. Together, these shifts are creating a more dynamic environment in which clinical efficacy, economic value, and operational feasibility must all be addressed to achieve successful adoption.

Tariff dynamics in 2025 are prompting reassessments of global supply chains, sourcing strategies, and localized manufacturing decisions that impact treatment availability and operational resilience

The tariff environment in the United States in 2025 influences multiple dimensions of the MMA treatment ecosystem, affecting supply chains, pricing strategies, and cross-border procurement decisions. Import-dependent components such as specialized reagents, biologic intermediates, and gene therapy vectors can experience procurement challenges when tariff-driven cost adjustments occur, necessitating proactive sourcing strategies and inventory planning. These dynamics prompt manufacturers and distributors to revisit procurement contracts and contingency sourcing to preserve supply continuity and manage cost pressures.

Beyond procurement, tariffs can influence strategic decisions about where to localize manufacturing and assembly operations, especially for complex biologics and combination products that require specialized infrastructure. Companies may accelerate plans to onshore certain production activities or invest in regional manufacturing partnerships to mitigate tariff exposure and reduce lead time variability. Consequently, tariff considerations are increasingly integrated into commercial planning, risk assessments, and pricing frameworks to ensure that treatment accessibility and supply reliability remain resilient in the face of trade policy shifts.

A segmentation-informed synthesis linking treatment modalities, administration routes, distribution channels, and age cohorts to strategic clinical and commercial imperatives

A granular view of segmentation reveals how therapeutic selection, distribution models, administration routes, and patient demographics interact to shape clinical choices and commercial pathways. Based on Treatment Type, the market is considered across Dietary Management, Enzyme Replacement Therapy, Gene Therapy, Hematopoietic Stem Cell Transplantation, and Liver Transplantation, with Dietary Management further delineated into L-Carnitine Supplementation, Low-Protein Diet, and Vitamin B12 Supplementation; this set of treatment modalities reflects a continuum from supportive care to potentially curative interventions and underscores the need to align evidence generation with long-term outcome measures. Based on Distribution Channel, the market is studied across Hospital Pharmacy and Retail Pharmacy, which highlights how care settings and dispensing infrastructure influence access, adherence, and patient support services. Based on Route Of Administration, the market is studied across Intravenous and Oral options, emphasizing how administration logistics, setting of care, and patient lifestyle considerations govern therapeutic adoption. Based on Patient Age Group, the market is studied across Adult, Infant, and Pediatric cohorts, which calls attention to the heterogeneity in clinical presentation, dosing strategies, and monitoring requirements across the lifespan.

Taken together, these segmentation lenses reveal critical intersections: for example, advanced therapies that require intravenous delivery and hospital-based administration will face different access barriers than oral supportive treatments available through retail pharmacy channels. Similarly, therapeutic strategies for infants and pediatric patients often prioritize early intervention and newborn screening linkages, whereas adult treatment pathways may emphasize chronic disease management and quality-of-life measures. This segmentation-informed perspective is essential for tailoring clinical development plans, patient support programs, and commercial strategies to the nuanced needs of each subgroup.

Regional differences in diagnostics, regulatory pathways, and healthcare infrastructure create distinct strategic priorities across the Americas, EMEA, and Asia-Pacific

Regional dynamics play a pivotal role in shaping the clinical, regulatory, and commercial contours of MMA management, with each geography presenting distinct opportunities and constraints. In the Americas, healthcare systems display variability in reimbursement practices and newborn screening programs, which affects the timing of diagnosis and the uptake of novel therapies. This region also hosts a concentration of specialized treatment centers and clinical research activity, fostering opportunities for rapid iteration in trial design and real-world evidence collection. Patient advocacy networks in this region often engage actively in policy and payer discussions, influencing access pathways.

Europe, Middle East & Africa exhibit heterogeneity in regulatory pathways and health technology assessment processes, with differences in national reimbursement criteria that influence the sequencing of market entry strategies. Stakeholders operating here must navigate multiple national systems while designing pan-regional evidence generation plans. Meanwhile, Asia-Pacific features diverse healthcare infrastructures and rapid uptake of innovative care models in select markets, alongside growing investment in local manufacturing capabilities and public-private partnerships. Across all regions, coordinated efforts to standardize diagnostic protocols, expand newborn screening, and strengthen registries will be instrumental in improving care continuity and enabling cross-border collaboration for clinical trials and post-market surveillance.

Industry players are differentiating through pipeline innovations, manufacturing partnerships, and integrated patient support models that align clinical value with real-world evidence

Key company activities and strategic postures are shaping the competitive landscape, with stakeholders differentiating through clinical pipelines, partnerships, and evidence-focused engagements. Some organizations concentrate on advancing gene therapy platforms toward durable disease modification, channeling investment into vector optimization, manufacturing scale-up, and long-term safety monitoring protocols. Others emphasize enzyme replacement approaches and supportive care solutions that can be integrated into existing clinical workflows, prioritizing incremental efficacy gains and improved tolerability.

Across the ecosystem, collaboration is a hallmark strategy: biopharma firms, academic centers, and contract development and manufacturing organizations are forming alliances to accelerate translation from bench to bedside. Commercially, companies are expanding patient support services and digital health integrations to address adherence and monitoring needs, while simultaneously engaging with payers to define value frameworks that reflect the longitudinal nature of treatment benefits. The aggregate effect is a landscape where therapeutic differentiation is increasingly tied to holistic offerings that combine clinical efficacy with robust support infrastructure and credible real-world evidence generation.

Practical, evidence-driven steps for translating scientific advances into accessible, sustainable care through partnerships, manufacturing resilience, and payer engagement

Industry leaders can take decisive steps to align scientific promise with durable patient impact by prioritizing coordinated strategies across development, regulatory engagement, and commercial readiness. First, integrating outcomes that matter to patients, caregivers, and payers into clinical development plans will strengthen reimbursement dialogues and support longer-term adoption. This means designing trials and registries that capture functional outcomes, quality-of-life metrics, and health economic endpoints alongside traditional biochemical markers.

Second, investing in flexible manufacturing and diversified supply chains can reduce exposure to trade policy disruptions and improve responsiveness to demand variability. Third, forging strategic partnerships with specialty treatment centers, advocacy groups, and diagnostic providers will accelerate patient identification, enhance adherence through comprehensive support services, and facilitate enriched enrollment for clinical studies. Finally, proactive payer engagement and transparent evidence plans should be established early to co-create value frameworks, pilot outcomes-based agreements where feasible, and clarify data requirements for national and regional decision-makers. Collectively, these actions will help translate scientific advances into tangible, equitable improvements in care.

A transparent multi-method research framework combining evidence synthesis, expert engagement, and cross-validation to support strategic decisions in MMA care

This research integrates a multi-method approach to ensure robust, reproducible insights relevant to clinical and commercial stakeholders. The methodology combines systematic literature reviews, regulatory document analysis, and synthesis of peer-reviewed clinical evidence with qualitative engagements such as structured interviews and expert advisory consultations. Data from clinical trial registries, guideline repositories, and public policy documents were triangulated to build a comprehensive understanding of therapeutic development and care pathways.

In addition, the analysis incorporates structured assessments of distribution channels, administration routes, and age-specific clinical considerations to contextualize findings within operational and patient-centric realities. Quality assurance procedures included cross-validation of key assertions against multiple independent sources, and sensitivity checks were applied to narrative conclusions where evidence heterogeneity existed. Where appropriate, methodological limitations are acknowledged and the implications for interpretation are made explicit, supporting transparent use of the insights for strategic decision-making.

Synthesizing clinical advances, operational readiness, and stakeholder collaboration to ensure innovations in methylmalonic acidemia translate into lasting patient impact

In conclusion, the treatment landscape for methylmalonic acidemia is at an inflection point where scientific progress, policy evolution, and operational realities converge to create new opportunities and responsibilities for stakeholders. Emerging therapies promise to change long-term disease trajectories, but realization of that promise depends on rigorous evidence generation, resilient supply chains, and collaborative payer and provider engagement. Early diagnosis through expanded newborn screening and integrated care models will be pivotal in enabling timely intervention and improved outcomes.

Looking ahead, success will favor organizations that adopt holistic strategies: those that align clinical development with patient-centered outcomes, invest in manufacturing and distribution agility, and proactively engage with payers and regulators to shape value frameworks. By doing so, stakeholders can better ensure that innovations translate into meaningful improvements in quality of life for patients living with MMA.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Methylmalonic Acidemia Treatment Market, by Treatment Type

  • 8.1. Dietary Management
    • 8.1.1. L-Carnitine Supplementation
    • 8.1.2. Low-Protein Diet
    • 8.1.3. Vitamin B12 Supplementation
  • 8.2. Enzyme Replacement Therapy
  • 8.3. Gene Therapy
  • 8.4. Hematopoietic Stem Cell Transplantation
  • 8.5. Liver Transplantation

9. Methylmalonic Acidemia Treatment Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral

10. Methylmalonic Acidemia Treatment Market, by Patient Age Group

  • 10.1. Adult
  • 10.2. Infant
  • 10.3. Pediatric

11. Methylmalonic Acidemia Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Retail Pharmacy

12. Methylmalonic Acidemia Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Methylmalonic Acidemia Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Methylmalonic Acidemia Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Methylmalonic Acidemia Treatment Market

16. China Methylmalonic Acidemia Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. AbbVie Inc.
  • 17.7. Acer Therapeutics Inc.
  • 17.8. Amgen Inc.
  • 17.9. Aurobindo Pharma Limited
  • 17.10. Baxter International Inc.
  • 17.11. BioMarin Pharmaceutical Inc.
  • 17.12. Dr. Reddy's Laboratories Ltd.
  • 17.13. Fresenius Kabi AG
  • 17.14. Homology Medicines, Inc.
  • 17.15. Johnson & Johnson
  • 17.16. Lupin Limited
  • 17.17. Merck & Co., Inc.
  • 17.18. Moderna, Inc.
  • 17.19. Nestle Health Science S.A.
  • 17.20. Nutricia B.V.
  • 17.21. OrphanPacific, Inc.
  • 17.22. Reckitt Benckiser Group plc
  • 17.23. REGENXBIO Inc.
  • 17.24. Rocket Pharmaceuticals, Inc.
  • 17.25. Sun Pharmaceutical Industries Ltd.
  • 17.26. Takeda Pharmaceutical Company Limited
  • 17.27. Teva Pharmaceutical Industries Ltd.
  • 17.28. Ultragenyx Pharmaceutical Inc.
  • 17.29. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY L-CARNITINE SUPPLEMENTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY L-CARNITINE SUPPLEMENTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY L-CARNITINE SUPPLEMENTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY LOW-PROTEIN DIET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY LOW-PROTEIN DIET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY LOW-PROTEIN DIET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY VITAMIN B12 SUPPLEMENTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY VITAMIN B12 SUPPLEMENTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY VITAMIN B12 SUPPLEMENTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY LIVER TRANSPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY LIVER TRANSPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY LIVER TRANSPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY INFANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY INFANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY INFANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. GCC METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GCC METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. GCC METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 111. GCC METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. GCC METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GCC METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. G7 METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. G7 METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. G7 METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 129. G7 METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. G7 METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. G7 METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. NATO METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. NATO METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. NATO METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 135. NATO METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. NATO METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. NATO METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA METHYLMALONIC ACIDEMIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)